Calidi Biotherapeutics Advances Cancer Immunotherapy Platform, Reduces Quarterly Losses
Calidi Biotherapeutics has made significant progress in its oncology research, receiving FDA clearance for a stem cell-based immunotherapy and presenting promising data on its Redtail virotherapy platform while simultaneously reducing operational expenses.
Calidi Biotherapeutics has reported a narrowing of its first quarter net losses to $5.0 million, down from $7.2 million in the previous year, while advancing its cancer treatment research and expanding its leadership team.
The biotech company achieved a significant milestone with FDA clearance of its Investigational New Drug (IND) application for CLD-201, an allogeneic stem cell-based immunotherapy targeting solid tumors. At the American Association for Cancer Research (AACR) conference, the company presented promising data on its Redtail platform, demonstrating the potential of delivering IL15 superagonist via an engineered oncolytic virus.
Key leadership additions include the appointment of Dr. Eric Poma as CEO and Dr. Guy Clifton as Chief Medical Officer, signaling strategic positioning for future development. The company's innovative approach focuses on developing systemic virotherapies that target metastatic cancers using proprietary stem cell-based platforms.
Calidi's unique technology aims to enhance the immune system's ability to combat cancer by utilizing allogeneic stem cells capable of carrying oncolytic viruses. This dual approach potentially offers a novel method for treating and potentially preventing metastatic disease across multiple oncological indications, including high-grade gliomas and solid tumors.